When was Imvax founded?

Imvax was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Where is Imvax located?

Imvax is headquartered in Philadelphia, United States.

How many employees does Imvax have?

As of Mar 01, 2026, the latest employee count at Imvax is 10 - 49.

Is Imvax a funded company?

Imvax is a funded company, having raised a total of $204M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 16, 2017.

When was the latest funding round of Imvax?

Imvax's latest funding was a $***** Series C round on Jan 29, 2025, with participation from 0 investor.

Where does Imvax rank among its competitors?

Imvax ranks 1st amongst 54 active competitors, of which 19 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Basilea, which secured $13.3M in May, 2026.

Who are the top competitors of Imvax?

Imvax's top competitors include Basilea, BriaCell Therapeutics and Brenus Pharma. Among them, Basilea secured the most recent funding round in May, 2026.

Imvax - 2026 Company Profile, Team, Funding & Competitors

Company Details

Personalized immunotherapies targeting solid tumors, stimulating innate and adaptive immunity. This biopharmaceutical company is dedicated to turning the complexity of solid tumors against themselves through personalized, whole tumor-derived immunotherapies. Their unique platform captures a tumor’s full antigen signature and uses it to stimulate the patient’s innate and adaptive immunity against remaining tumor cells. They are developing a diverse pipeline of personalized treatments with promising clinical data in Glioblastoma and preclinical data in multiple other solid tumors. The company focuses on research & development strategy and activities, clinical development, and potential product development to deliver therapies targeting solid tumors. They are committed to innovation in the field of personalized immunotherapy.

Website: www.imvax.com/
Social
Email ID: *****@imvax.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

Philadelphia, United States

Stage

Series C

Total Funding

$204M in 5 rounds

Latest Funding Round

Series C, Jan 29, 2025, $*****

Investors

Hp Wild Holding & 5 more

Ranked

1^st among 54 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Basilea & 56 more

View Imvax's full profile

Imvax is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Imvax, Inc. CIN: 81-0881154 , United States, Active	Nov 17, 2015	-	50 (As on Dec 31, 2021)	-

Imvax has raised a total funding of $204M over 5 rounds. Its first funding round was on Jun 16, 2017. Imvax has 6 institutional investors.

Here is the list of recent funding rounds of Imvax:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 29, 2025	4558554	Series C	3600344	2479702	2402318	7552736
Sep 06, 2023	6459821	Series C	7796317	7455162	7572865	5714644
Jul 16, 2020	9117815	Series C	3112171	6354148	Hp Wild Holding	Magnetar & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Imvax's funding rounds and investors

The founders of Imvax are David Andrews and Craig Hooper.

Here are the details of Imvax's key team members:

David Andrews: Co-Founder & Chief Medical Officer of Imvax.
Contact Info: 1 email address
Craig Hooper: Co-Founder & CSO of Imvax.

View details of Imvax's Founder profiles and Board Members

Imvax's employee count trend

Imvax has 10 - 49 employees as of Mar 26. Here is Imvax's employee count trend over the years:

Uncover Imvax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Imvax include Basilea, BriaCell Therapeutics and Brenus Pharma. Here is the list of Top 10 competitors of Imvax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Imvax 2015, Philadelphia (United States), Series C	Personalized immunotherapies targeting solid tumors, stimulating innate and adaptive immunity	$204M	Invus, Magnetar & 4 others	63/100
2nd	Basilea 1999, Basel (Switzerland), Public	Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases	-	Athyrium Capital Management, Medical Countermeasures ... & 2 others	59/100
3rd	BriaCell Therapeutics 2004, Beverly Hills (United States), Public	Developer of immunotherapies for the treatment of cancer	-	National Cancer Institute, ThinkEquity & 5 others	58/100
4th	Brenus Pharma 2020, Issoire (France), Series A	Developer of immunotherapy for the treatment of cancer	$25M	UI Investissement, Capitaletcroissance.be ... & 3 others	54/100
5th	SOM Biotech 2009, Barcelona (Spain), Series B	Developer of platform for screening compounds to treat rare diseases	$28.5M	European Investment Bank, Prevail Partners ... & 3 others	53/100
6th	Vaximm 2008, Basel (Switzerland), Series A	Developing active immunotherapies (vaccines) for patients suffering from cancer.	$8.33M	Sunstone, Merck & 4 others	50/100
7th	Ayala Pharma 2017, Wilmington (United States), Public	Developer of small molecule-based therapeutics for cancer treatment	$50.6M	Novartis, Bristol-Myers Squibb & 9 others	49/100
8th	Immunorock 2021, Kobe (Japan), Seed	Developer of immunotherapies for the treatment of cancer and infectious diseases	$2.59M	Osaka University Venture Capital, SBI Daigaku Hatsu Venture Ikusei Shien ... & 3 others	47/100
9th	Photonpharma 2019, Fort Collins (United States), Seed	Provider of antigen presentation technology	$5.76M	-	47/100
10th	Argent BioPharma 2023, London (United Kingdom), Public	Drug discovery company focused on the central nervous system and immunology	-	-	47/100